Home › NDC Lookup › RxCUI directory › RxCUI 1046771

12 HR hyoscyamine sulfate 0.375 MG Extended Release Oral Tablet [Levbid] — RxCUI 1046771

RxNorm drug concept · Semantic branded drug
RxCUI 1046771 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1046771
Official name12 HR hyoscyamine sulfate 0.375 MG Extended Release Oral Tablet [Levbid]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as12 HR Levbid 0.375 MG Extended Release Oral Tablet; Levbid 0.375 MG 12HR Extended Release Oral Tablet
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Hyoscyamine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Hyoscyamine calms spasms and slows secretions in the stomach, bowel and bladder. It is often an add-on for peptic ulcer or irritable bowel syndrome. Some products have additional u...
  • Many tablets are taken 30 to 60 minutes before meals and at bedtime, and some are taken as needed. Follow your label, since dissolving, under-the-tongue and extended-release forms...
  • Dry mouth, blurred vision, drowsiness, dizziness and constipation are common. Use caution driving until you know how it affects you. Call your doctor if you cannot urinate or feel...
  • Be careful. Hyoscyamine reduces sweating, so you can overheat and even get heat stroke. Stay cool and get help for fever or heat illness.
📖 Read our full Hyoscyamine guide →

🕸️ Concept Web — How 12 HR hyoscyamine sulfate 0.375 MG Extended Rele... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 12 HR hyoscyamine sulfate 0.375 MG Extended Release Oral Tablet [Levbid] RxCUI 1046771

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Hyoscyamine 153970
    • Hyoscyamine sulfate 1225
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Levbid 217993
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Hyoscyamine Extended Release Oral Tablet 378214
    • Hyoscyamine sulfate Extended Release Oral Tablet 2645454
    • Hyoscyamine Oral Product 1165278
    • Hyoscyamine Pill 1165279
    • Hyoscyamine sulfate Oral Product 2659505
    • Hyoscyamine sulfate Pill 2661552
    • Hyoscyamine Extended Release Oral Tablet [Levbid] 370308
    • Hyoscyamine sulfate Extended Release Oral Tablet [Levbid] 2656903
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 12 HR hyoscyamine sulfate 0.375 MG Extended Release Oral Tablet SCD · 1046770
  • Hyoscyamine sulfate 0.375 MG SCDC · 1044607
  • Hyoscyamine Extended Release Oral Tablet SCDF · 378214
  • Hyoscyamine sulfate Extended Release Oral Tablet SCDFP · 2645454
  • Hyoscyamine Oral Product SCDG · 1165278
  • Hyoscyamine Pill SCDG · 1165279
  • Hyoscyamine sulfate Oral Product SCDGP · 2659505
  • Hyoscyamine sulfate Pill SCDGP · 2661552

Brand-Name Concepts

  • Hyoscyamine sulfate 0.375 MG [Levbid] SBDC · 1046763
  • Hyoscyamine Extended Release Oral Tablet [Levbid] SBDF · 370308
  • Hyoscyamine sulfate Extended Release Oral Tablet [Levbid] SBDFP · 2656903
  • Levbid Oral Product SBDG · 1167930
  • Levbid Pill SBDG · 1167931
  • Levbid BN · 217993

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 1046771 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
68220-0115-10 1 TABLET, EXTENDED RELEASE in 1 BOTTLE (68220-115-10) Levbid Viatris Specialty LLC 2008-12-01
Observed labelers: Viatris Specialty LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.